Category News

Blueprint Medicines Showcases Leadership in Systemic Mastocytosis at 2024 ASH Meeting

Blueprint Medicines Corporation presented compelling new data at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the long-term benefits of AYVAKIT® (avapritinib) in treating systemic mastocytosis (SM). These findings reflect the company’s commitment to transforming patient care through…

Read MoreBlueprint Medicines Showcases Leadership in Systemic Mastocytosis at 2024 ASH Meeting

Revolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio

Revolution Medicines a clinical-stage oncology company developing targeted therapies for RAS-driven cancers, announced significant clinical updates from its RAS(ON) inhibitor portfolio. The data, presented during an investor webcast, focused on the Phase 1 RMC-6236 monotherapy study in pancreatic ductal adenocarcinoma…

Read MoreRevolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio